Havrix Junior

Havrix Junior is an injectable hepatitis A vaccine that contains inactivated hepatitis A virus adsorbed on aluminium hydroxide. It is supplied as a sterile solution for intramuscular administration and is prescribed in the European Union. The vaccine is designed to stimulate active immunity against hepatitis A infection, primarily in pediatric patients, by prompting the body to produce protective antibodies and to contribute to community health protection.

Havrix Junior is indicated for the prevention of hepatitis A infection in children and is part of routine immunization schedules in many countries.

- Primary prophylaxis against hepatitis A virus in children aged 12 months and older. - Completion of a two‑dose series, typically administered six months apart. - Use in outbreak settings to quickly establish herd immunity among pediatric populations. - Administration before travel to regions where hepatitis A is endemic. - Inclusion in combined vaccination programs when a hepatitis A vaccine is required.

Like other vaccines, Havrix Junior may cause mild to moderate reactions, most of which resolve without medical intervention.

Common: - Pain, redness, or swelling at the injection site. - Low‑grade fever (temperature <38.5 °C). - Headache or mild fatigue. - Transient loss of appetite.

Serious: - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Neurological events including Guillain‑Barré syndrome. - Persistent high fever or severe systemic illness.

Healthcare providers should assess individual risk factors and medical history before administering Havrix Junior to ensure safe vaccination.

- Defer vaccination in children with a known severe allergy to any vaccine component, including aluminium hydroxide. - Postpone if the child has an acute moderate or severe illness with fever. - Use caution in individuals with a history of Guillain‑Barré syndrome. - Evaluate immunocompromised patients on a case‑by‑case basis, as response may be reduced. - Discuss pregnancy and breastfeeding status; data are limited, and vaccination decisions should follow local guidelines. - Monitor for signs of anaphylaxis for at least 15 minutes after injection.

Havrix Junior generally has a low potential for drug interactions, but certain concomitant therapies may influence its safety or effectiveness.

Avoid: - Simultaneous administration of other injectable vaccines containing live attenuated viruses, which may interfere with immune response. - Use of systemic corticosteroids at immunosuppressive doses immediately before or after vaccination.

Use with caution: - Antipyretics (e.g., acetaminophen or ibuprofen) may mask low‑grade fever; they can be given after vaccination if needed. - Immunoglobulin or blood products given within four weeks before or after vaccination may reduce antibody response. - Antihistamines may be used to manage mild allergic reactions but do not prevent serious hypersensitivity.